Table 2. Kinase peptide substrates with significantly affected (reduced or increased) phosphorylation levels by samples from androgen-deprived (AD), long-term AD (ADL), or castration-resistant (CR) prostate carcinoma xenografts, versus androgen-deprivation therapy (ADT)-naïve xenografts.
| Kinase peptide substratea | Peptide start positionb | Peptide end positionb | Site(s) of phosphorylationc | Gene named | Common namee |
| Angiogenesis f | |||||
| EGFR | 1103 | 1115 | Y1110 | EGFR | Epidermal growth factor receptor |
| EPHA4 | 921 | 933 | Y928 | EPHA4 | Ephrin type A receptor 4 |
| EPOR | 361 | 373 | Y368 | EPOR | Erythropoietin receptor |
| PECA1 | 706 | 718 | Y713 | PECAM1 | Platelet endothelial cell adhesion molecule |
| PGFRB | 1002 | 1014 | Y1009 | PDGFRB | Platelet-derived growth factor receptor beta |
| PGFRB | 768 | 780 | Y771/775/778 | PDGFRB | Platelet-derived growth factor receptor beta |
| PGFRB | 771 | 783 | Y771/775/778 | PDGFRB | Platelet-derived growth factor receptor beta |
| P85A | 600 | 612 | Y607/S608 | PIK3R1 | Phosphatidylinositol 3-kinase regulatory subunit alpha |
| VGFR1 | 1326 | 1338 | Y1327/1333 | FLT1g | Vascular endothelial growth factor receptor 1 |
| VGFR2 | 989 | 1001 | Y996 | KDRg | Vascular endothelial growth factor receptor 2 |
| Survival/proliferation/progression | |||||
| 41 | 654 | 666 | Y660 | EPB41 | Erythrocyte membrane protein band 4.1 |
| CDK2 | 8 | 20 | Y15/19 | CDK2 | Cyclin-dependent kinase 2 |
| ENOG | 37 | 49 | Y44 | ENO2 | Gamma enolase 2 |
| FRK | 380 | 392 | Y387 | FRK | Fyn-related kinase |
| MK01 | 180 | 192 | Y187 | MAPK1 | Mitogen-activated protein kinase 1 |
| MK10 | 216 | 228 | Y223/228 | MAPK10 | Mitogen-activated protein kinase 10 |
| NTRK2 | 696 | 708 | Y702/706/707 | NTRK2 | Neutrotrophic tyrosine kinase receptor 2 |
| PDPK1 | 2 | 14 | Y9 | PDPK1 | 3-phosphoinositide dependent protein kinase 1 |
| PRGR | 786 | 798 | Y795 | PGR | Progesterone receptor |
| PRRX2 | 202 | 214 | Y208/214 | PRRX2 | Paired-related homeobox protein 2 |
| RAF1 | 332 | 344 | Y340/341 | RAF1 | Raf proto-oncogene serine/threonine protein kinase |
| RET | 1022 | 1034 | Y1029 | RET | Ret proto-oncogene tyrosine protein kinase receptor |
| STAT1 | 694 | 706 | Y701 | STAT1 | Signal transducer and activator of transcription 1 |
| STA5A | 687 | 699 | Y694 | STAT5A | Signal transducer and activator of transcription 5A |
| TYRO3 | 679 | 691 | Y681/685/686 | TYRO3 | Tyro3 tyrosine protein kinase receptor |
| Adhesion/migration/invasion | |||||
| EFS | 246 | 258 | Y253 | EFS | Embryonal Fyn-associated substrate |
| FER | 707 | 719 | Y714 | FER | Fer proto-oncogene tyrosine protein kinase |
| FES | 706 | 718 | Y713 | FES | Fes/Fps proto-oncogene tyrosine protein kinase |
| MET | 1227 | 1239 | Y1230/1234/1235 | MET | Hepatocyte growth factor receptor |
| PAXI | 111 | 123 | Y118 | PXN | Paxillin |
| PAXI | 24 | 36 | Y31/33 | PXN | Paxillin |
| PLCG1 | 764 | 776 | Y771/775 | PLCG1 | Phospholipase C gamma 1 |
| SRC8 | 476 | 488 | Y477/483 | CTTN1 | Src substrate protein p85 (cortactin) |
| SRC8 | 492 | 504 | Y492/499/502 | CTTN1 | Src substrate protein p85 (cortactin) |
| Other | |||||
| CD79A | 181 | 193 | Y182/188 | CD79A | B-cell antigen receptor complex-associated protein alpha-chain |
a
Kinase peptide substrate names on the Tyrosine Kinase PamChip® microarray.
b
Start and end positions for the kinase peptide sequence within the protein.
c
Site(s) of tyrosine phosphorylation within the protein.
d
Corresponding gene names and ecommon names, retrieved from UniProt or HUGO Gene Nomenclature Committee (HGNC).
f
Kinase peptide substrates are grouped according to the main cellular process they are involved in.
g
FLT1 and KDR are also known as VEGFR1 and VEGFR2.